Miraculins Announces PreVu(R) Test Expansion into Ontario and

Miraculins Announces PreVu(R) Test Expansion into Ontario and
Atlantic Canada through PharmaChoice(R) Drug Stores 
Cholesterol Measured in Skin is New Risk Marker for Coronary Artery
WINNIPEG, MANITOBA -- (Marketwire) -- 01/07/13 -- Miraculins Inc.
(TSX VENTURE:MOM), a medical diagnostic company focused on acquiring,
developing and commercializing diagnostic tests and risk assessment
technologies for unmet clinical needs; PharmaChoice, one of Canada's
largest pharmacy networks comprised of over 350 independently-owned
stores; and Pear Healthcare Solutions, a leading provider of
in-pharmacy health screening and educational services, today announce
that PharmaChoice will be the first pharmacy network to introduce the
PreVu(R) Non-Invasive Skin Cholesterol Point of Care (POC) Test in
Ontario and Atlantic Canada, through a Phase One launch in up to 50
of its stores this February - Canada's National Heart Health Month.   
"At PharmaChoice, we are committed to providing the highest standard
of health care and advice to our patients, and we are very pleased to
be the first pharmacy in Eastern Canada to introduce the PreVu POC
Test to patients through our network of independently-owned and
operated community pharmacies," said Lowell Johnstone, Director of
Pharmacy Services, PharmaChoice. "PreVu represents a perfect fit for
our pharmacies which encourage preventative healthcare within the
communities they serve. With this important new non-invasive
technology, we can identify patients who may be at higher risk for
coronary artery disease. We are confident that the availability of
this service in PharmaChoice pharmacies will raise heart health
awareness for Canadians."  
"We are very excited to be expanding PreVu into Eastern Canada
through PharmaChoice, one of the country's most respected and
forward-thinking retail pharmacy operations," said Paul Moreau, Vice
President, Sales and Marketing for Miraculins Inc. "Ontario and the
Atlantic provinces represent significant markets for us and our
retail launch through PharmaChoice will provide us with access to
millions of consumers who have come to trust the PharmaChoice brand
in its delivery of neighborhood-based wellness advice and services.
As an industry leader, PharmaChoice understands the critical
importance of
 raising heart disease awareness at the grassroots level
and by using the PreVu test, will be able to identify individuals at
risk who could benefit from more intensive primary prevention
measures directed by their doctors to help guard against a first
heart attack."   
PreVu will be introduced this February during National Heart Health
Month in up to 50 PharmaChoice locations spread out across Ontario,
New Brunswick, Prince Edward Island, Nova Scotia and Newfoundland, as
part of a Phase One launch of the new test through the PharmaChoice
network. This introductory campaign will see the PreVu POC Test
conducted in-store by PharmaChoice pharmacists as part of a series of
special PreVu Cardiovascular Risk Assessment Clinics. Phase Two of
the expansion will see additional PharmaChoice locations being added
in the months that follow, with all participating stores anticipated
to transition to offering PreVu testing as an ongoing risk assessment
service available either through walk-up request or by appointment.
Further details as to participating store locations for Phase One
will be released closer to February. 
Based upon a patient's PreVu test results, formal risk assessment
under their healthcare provider's direction, including blood
cholesterol testing and global risk assessment, may be warranted, or
should be considered. The PreVu POC Test does not diagnose the
presence or absence of coronary artery disease (CAD), but without
blood draw or fasting it can quickly identify individuals who may
possess hidden, higher levels of risk of CAD by measuring their skin
cholesterol levels, and encouraging them to see their doctors.
Clinical studies have shown that elevated skin cholesterol is
strongly associated with an increased risk of serious atherosclerotic
disease. PreVu is not a substitute for blood serum cholesterol
About The PreVu(R) Non-Invasive Skin Cholesterol Test 
The PreVu(R) Point of Care (POC) Test is a non-invasive, risk
assessment technology designed to measure Skin Cholesterol - an
important new biomarker in assessing risk of coronary artery disease
(CAD). The PreVu(R) POC Test is completely painless, non-invasive,
involves no blood draw or needles, and requires no overnight fasting.
This in vitro diagnostic test is conducted on the palm of the hand in
less than 5 minutes with results being immediately available,
facilitating point of care consultation and a next steps discussion.
Skin Cholesterol is the cholesterol that has been deposited and
diffused into tissue, as opposed to freely circulating in the
bloodstream, and the skin contains approximately 11% of all the
cholesterol found in the human body. Elevated Skin Cholesterol has
been shown in clinical studies to be strongly associated with
significant CAD as measured by treadmill stress testing and coronary
angiography, as well as measured by testing for coronary calcium,
carotid artery thickening, and carotid artery plaque. The PreVu(R)
Point of Care Test does not diagnose the presence or absence of CAD,
but helps to identify patients who may be at higher, hidden risk for
CAD by measuring this new biomarker. For more information visit
About Miraculins Inc. 
Miraculins is a medical diagnostic company focused on acquiring,
developing and commercializing non-invasive tests for unmet clinical
needs. A significant number of promising diagnostic opportunities
remain un-commercialized because of the sizable gap between the
discovery stage, when research institutions are typically involved,
and the commercialization stage, when the larger commercial
enterprises become interested. Miraculins has direct experience in
bridging this gap. The Company's PreVu(R) technology is a
revolutionary new coronary artery disease risk assessment technology
that measures cholesterol levels in a patient's skin non-invasively,
painlessly and without the need for fasting. Miraculins is also
advancing a suite of biomarkers to aid in the early detection of the
devastating disease of pregnancy known as preeclampsia. The Company's
preeclampsia program is partnered with Alere Inc. (formerly known as
Inverness Medical Innovations), one of the world's largest diagnostic
companies. For more information visit www.miraculins.com.  
About PharmaChoice  
Based in Dartmouth, Nova Scotia, PharmaChoice is a member-owned
cooperative that represents independent pharmacy owners across
Canada. Launched in 1999, PharmaChoice empowers independent drug
stores to combine professional services with a wide range of
competitively priced products adapted to customer needs. The
PharmaChoice philosophy is embodied in the slogan "Advice for Life"
and the organization lives that promise everyday as an integral part
of healthcare in the communities it serves. There are over 350
locations that rely on the strength of the PharmaChoice brand to
leverage their buying power and supply them with various marketing
programs. PharmaChoice delivers the following services to its
membership: Buying Power; Marketing Tools; Technology Solutions;
Value Added Programs; and Best Practices. As such the pharmacists'
role is seen as that of recognized community leader, whose commitment
to their patients make them an important member of their patient's
health care team
. In addition to counseling and responding to
people's health and wellness queries, the pharmacist is also a
patient's best friend. Head Office backs PharmaChoice members with a
robust support system that provides an array of innovative ways for
pharmacists to remain committed to their patients. For more
information visit www.pharmachoice.com.  
About Pear Healthcare Solutions 
Pear Healthcare Solutions is a privately held company specializing in
the development and implementation of programs to address the
evolving needs of pharmacists in their expanding role of providing
healthcare and disease management services. Pear Healthcare Solutions
offers a number of innovative medical devices and professional
education programs that help pharmacies connect with their patients,
improving their health and wellness. Pear provides distribution,
training and support/education services. For more information visit
Caution Regarding Forward-Looking Information  
Certain statements contained in this press release constitute
forward-looking information within the meaning of applicable Canadian
provincial securities legislation (collectively, "forward-looking
statements"). These forward-looking statements relate to, among other
things, our objectives, goals, targets, strategies, intentions,
plans, beliefs, estimates and outlook, including, without limitation,
our anticipated future operating results, and can, in some cases, be
identified by the use of words such as "believe," "anticipate,"
"expect," "intend," "plan," "will," "may" and other similar
expressions. In addition, any statements that refer to expectations,
projections or other characterizations of future events or
circumstances are forward-looking statements.  
These statements reflect management's current beliefs and are based
on information currently available to management. Certain material
factors or assumptions are applied in making forward-looking
statements, and actual results may differ materially from those
expressed or implied in such statements. Important factors that could
cause actual results to differ materially from these expectations
include, among other things: Miraculins' early stage of development,
lack of product revenues and history of operating losses,
uncertainties related to clinical trials and product development,
rapid technological change, uncertainties related to forecasts,
competition, potential product liability, additional financing
requirements and access to capital, unproven markets, supply of raw
materials, income tax matters, management of growth, partnerships for
development and commercialization of technology, effects of insurers'
willingness to pay for products, system failures, dependence on key
personnel, foreign currency risk, risks related to regulatory matters
and risks related to intellectual property and other risks detailed
from time to time in Miraculins' filings with Canadian securities
regulatory authorities, as well as Miraculins' ability to anticipate
and manage the risks associated with the foregoing. Additional
information about these factors and about the material factors or
assumptions underlying such forward-looking statements may be found
in the body of this news release. Miraculins cautions that the
foregoing list of important factors that may affect future results is
not exhaustive. When relying on Miraculins' forward-looking
statements to make decisions with respect to Miraculins investors and
others should carefully consider the foregoing factors and other
uncertainties and potential events.  
These risks and uncertainties should be considered carefully and
prospective investors should not place undue reliance on the
forward-looking statements. Although the forward-looking statements
contained in this press release are based upon what management
believes to be reasonable assumptions, Miraculins cannot provide
assurance that actual results will be consistent with these
forward-looking statements. Miraculins undertakes no obligation to
update or revise any forward-looking statement.  
PreVu(R) is a registered trademark of Miraculins Inc. All Rights
Reserved. 2013.  
PharmaChoice(R) is a registered trademark of PharmaChoice. All Rights
Reserved. 2013.  
Neither the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release. 
Miraculins Inc.
Paul Moreau
Vice President, Sales & Marketing
204-453-1546 (FAX) 
Miraculins Inc.
Christopher J. Moreau
President and CEO
204-453-1546 (FAX)
Press spacebar to pause and continue. Press esc to stop.